This Study Uses Ultrasound to Determine Whether Atorvastatin or Pravastatin Effects the Progression of Coronary Plaque.
NCT00380939
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
- Angiographic evidence of coronary artery disease as defined by a lesion that has at least 20% reduction in luman diameter by visual (angiographic) estimation in any native coronary artery. LDL cholesterol equal to 125mg/dl - 210mg/dl.
- Patients who are anticipated to undergo coronary bypass surgery or cardiac
transplantation during the course of the study. Known major hematologic, neoplastic,
metabolic, gastrointestinal or endocrine dysfunction.
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Little Rock, Arkansas
- Los Angeles, California
- Los Angeles, California
- San Diego, California
- Denver, Colorado
- Blue Island, Florida
- Gainesville, Florida
- Atlanta, Georgia
- Chicago, Illinois
- Shawnee Mission, Kansas
- Louisville, Kentucky
- Auburn, Maine
- Boston, Massachusetts
- Kalamazoo, Michigan
- Royal Oak, Michigan
- St Clair, Michigan
- Rochester, Minnesota
- Albany, New York
- New York, New York
- Williamsville, New York
- Chapel Hill, North Carolina
- Greensboro, North Carolina
- Greenville, North Carolina
- Winston Salem, North Carolina
- Cleveland, Ohio
- Cleveland, Ohio
- Columbus, Ohio
- Elryia, Ohio
- Toledo, Ohio
- Tulsa, Oklahoma
- Allentown, Pennsylvania
- Philadelphia, Pennsylvania
- Providence, Rhode Island
- Providence, Rhode Island
- San Antonio, Texas
- Seattle, Washington
Descriptive Information | ||||
---|---|---|---|---|
Brief Title ICMJE | This Study Uses Ultrasound to Determine Whether Atorvastatin or Pravastatin Effects the Progression of Coronary Plaque. | |||
Official Title ICMJE | A Prospective, Randomized, Double-Blind, Multi-Center Study Comparing the Effects of Atorvastatin Versus Pravastatin on the Progression and Quantification of Coronary Atherosclerotic Lesions as Measured by Intravascular Ultrasound (REVERSAL) | |||
Brief Summary | This study was designed to assess the effects on coronary artery plaque using aggressive lipid-lowering therapy versus moderate lipid-lowering therapy. A substudy will examine the effect of these treatments on brachial artery vasoactivity. | |||
Detailed Description | Not Provided | |||
Study Type ICMJE | Interventional | |||
Study Phase ICMJE | Phase 4 | |||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Primary Purpose: Treatment | |||
Condition ICMJE | Coronary Arteriosclerosis | |||
Intervention ICMJE |
| |||
Study Arms ICMJE | Not Provided | |||
Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
Recruitment Information | ||||
Recruitment Status ICMJE | Completed | |||
Enrollment ICMJE | 600 | |||
Original Enrollment ICMJE | Same as current | |||
Study Completion Date ICMJE | December 2000 | |||
Primary Completion Date | Not Provided | |||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| |||
Sex/Gender ICMJE |
| |||
Ages ICMJE | 30 Years to 75 Years (Adult, Older Adult) | |||
Accepts Healthy Volunteers ICMJE | No | |||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries ICMJE | United States | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number ICMJE | NCT00380939 | |||
Other Study ID Numbers ICMJE | 0981-400-314 | |||
Has Data Monitoring Committee | Not Provided | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement ICMJE | Not Provided | |||
Responsible Party | Not Provided | |||
Study Sponsor ICMJE | Pfizer | |||
Collaborators ICMJE | Not Provided | |||
Investigators ICMJE |
| |||
PRS Account | Pfizer | |||
Verification Date | November 2006 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |